Genmab — Marts 2020
-
Vincent Rajkumar
@VincentRK
·
7 t
Today @US_FDA
@FDAOncology
approved isatuximab (Sarclisa) for relapsed refractory myeloma.Im happy that @SanofiUS
has priced it significantly lower than daratumumab. I hope there is a price war, & prices drop more. Based on cost, I’ll prefer Isa-PomDex to Dara-PomDex. @mtmdphd -
Vincent Rajkumar
@VincentRK
·
7 t
I was an author on the isatuximab pivotal trial. Im working with both @sanofi
and @JanssenUS
on other trials.Look forward to thoughts on how we support the appropriate choice of drug taking cost into account from @Rfonsi1
@akeithstewart
@peterbachmd
& others who are interested -
#ACTRIMS2020 – Results of Ofatumumab Self-injection Pen Equivalent to Infusion, APLIOS Trial Shows https://multiplesclerosisnewstoday.com/news-posts/2020/02/28/actrims2020-poster-session-lb300-onset-of-b-cell-depletion-with-subcutaneous-administration-of-ofatumumab-in-relapsing-multiple-sclerosis-results-from-the-aplios-bioequivalence-study
-
-
-
Det største problem med Sanofi er, at pt sælger Genmab mest med Daratumumab i kombination med POM-DEX, så det er lidt samme patientgrundlag. Tilsyneladende er denne kombi ogås meget brugt i anden linie, så spørgsmålet er om Sanofi også kan vinde indpas der med en lavere prissætning. Lad os håbe at sc dosering er en game changer som Jan siger - omvendt kan Sanofi indpas gøre det svært for JNJ at hæve prisen pt.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind